Vertex Stock in Focus After Deal to Buy Alpine Immune For $4.9B—Key Level to Watch

Key TakeawaysVertex shares slipped in extended trading Wednesday after the company announced it had agreed to acquire Alpine Immune Sciences for $4.9 billion.The deal values each Alpine share at $65, representing a 38% premium to Wednesday’s closing price of $47.04.The acquisition provides Vertex with access to Alpine’s mid-stage development antagonist povetacicept to treat a kidney autoimmune disease called IgA nephropathy (IgAN).The Vertex share price may find buying interest around $390 from an uptrend l ...